Clinical Trials Logo

Recurrent Malignant Neoplasm clinical trials

View clinical trials related to Recurrent Malignant Neoplasm.

Filter by:

NCT ID: NCT04409314 Completed - Clinical trials for Recurrent Plasma Cell Myeloma

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

Start date: April 16, 2020
Phase:
Study type: Observational

This study evaluates whether tumors present in patients with cancer who are planned to get CAR T-cells have low amounts of oxygen (hypoxia). PET scans may be used to check the amounts of oxygen within areas of cancer with a special radioactive tracer called FAZA that specifically looks for areas of low oxygen. This study is being done to help researchers determine how the amount of oxygen within areas of cancer affect how well CAR T-cells kill cancer cells.

NCT ID: NCT04186884 Completed - Clinical trials for Advanced Malignant Neoplasm

Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings

Start date: March 26, 2019
Phase:
Study type: Observational

This trial studies caregiver burden, quality of life, and symptom distress of patients and their informal (unpaid) caregivers at different palliative care settings. Cancer caregiving may affect a caregiver's life physically, emotionally, socially, and financially. Studying caregiver burden may help investigators learn about caregivers' opinions on stress of caregiving, and about the factors related to caregiver burdens.

NCT ID: NCT04089488 Completed - HIV Infection Clinical Trials

Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America

Start date: January 17, 2020
Phase:
Study type: Observational

This trial studies the frequency of incident and prevalent of cancer in people living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) at cancer centers in Latin America. By counting how many people living with HIV/AIDS have cancer at these specific centers, researchers may better understand how they are being treated and cared for. This may help researchers to understand what new studies may be helpful for those areas in the future.

NCT ID: NCT04059393 Completed - Clinical trials for Recurrent Malignant Neoplasm

PCRC-Supported Legacy Intervention in Pediatric Palliative Care

Start date: July 27, 2015
Phase: N/A
Study type: Interventional

This trial studies how well a web-based legacy intervention works in improving the quality of life in caregivers and younger patients with cancer that has come back (recurrent) or does not respond to treatment (refractory). Legacy-making, defined as doing or saying something to be remembered, may reduce the suffering of children with cancer and their caregivers. Currently, there is little information about what kinds of legacy-making activities are helpful from the perspective of children. Using a web-based digital storytelling intervention, this study may help researchers examine what children think about these legacy-making activities and what kinds of activities might be helpful to them.

NCT ID: NCT04053517 Active, not recruiting - Clinical trials for Advanced Malignant Neoplasm

Financial Distress in Advanced Cancer Patients

Start date: July 2, 2019
Phase:
Study type: Observational

This trial studies the severity of financial distress in advanced cancer patients. The cost of cancer care can often be very expensive. Financial distress from the burdens of high costs and debt may interfere with a patient's physical symptoms and quality of life.

NCT ID: NCT03856060 Active, not recruiting - Malignant Neoplasm Clinical Trials

Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits

Start date: March 30, 2019
Phase: N/A
Study type: Interventional

This trial assesses patient perception of physician's compassion, communication skills, and professionalism during clinic visits through the use of videos and questionnaires.

NCT ID: NCT03743649 Active, not recruiting - Delirium Clinical Trials

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Start date: July 17, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/IIII trial studies how well haloperidol and lorazepam work in controlling symptoms of persistent agitated delirium in patients with cancer that has spread to other places in the body undergoing palliative care. Haloperidol and lorazepam may help in controlling symptoms of agitated delirium in patients with cancer and may lessen any distress that their caregivers may be experiencing.

NCT ID: NCT03525873 Active, not recruiting - Clinical trials for Advanced Malignant Neoplasm

Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy

Start date: August 2, 2018
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well methylphenidate and physical activity works in reducing cancer-related fatigue in patients who are receiving anti-PD1 immunotherapy for cancer that has spread to other places in the body. Central nervous systems stimulants, such as methylphenidate, may help to improve cognitive function. Physical activity uses techniques, such as aerobic and resistance exercises, which may help to improve quality of life. Giving methylphenidate and physical activity may help in reducing cancer-related fatigue in patients with metastatic cancer who receive anti-PD1 immunotherapy.

NCT ID: NCT03439085 Active, not recruiting - Clinical trials for Recurrent Cervical Carcinoma

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Start date: November 14, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human papillomavirus associated cancers that have come back or spread to other places in the body. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and durvalumab may work better in treating patients with human papillomavirus associated cancers.

NCT ID: NCT03021486 Active, not recruiting - Delirium Clinical Trials

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

Start date: June 5, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This randomized phase II/III trial studies how well haloperidol with or without chlorpromazine works in treating delirium in patients with cancer that has spread to other parts of the body or has come back. Haloperidol and chlorpromazine may control the symptoms of delirium (loss of contact with reality) in patients with cancer.